Ignite Creation Date:
2024-05-06 @ 11:00 AM
Last Modification Date:
2024-10-26 @ 12:38 PM
Study NCT ID:
NCT03402711
Status:
UNKNOWN
Last Update Posted:
2018-01-18
First Post:
2018-01-11
Brief Title:
Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II
Status:
UNKNOWN
Status Verified Date:
2018-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI
Detailed Description:
Acute coronary syndrome ACS is a group of clinical syndromes characterized by rupture or erosion of coronary atherosclerotic plaques secondary to complete or incomplete thrombus formation
With the development of antithrombotic drugs and percutaneous coronary interventional therapy bleeding has become one of the major complications for ACS patients after PCIMoreoverBleeding after PCI therapy significantly increased short-term and long-term risk of death
However there is a lack of data on the risk of bleeding in ACS patients treated with PCI in the clinical reality world of china
Thereforethe present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI
The present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI
This study will provide sufficient and reliable evidence for the risk of bleeding and the choice of antithrombotic drugs in ACS patients undergoing PCI in China and provide a reference for individual antithrombotic therapy after PCI
With the development of antithrombotic drugs and percutaneous coronary interventional therapy bleeding has become one of the major complications for ACS patients after PCIMoreoverBleeding after PCI therapy significantly increased short-term and long-term risk of death
However there is a lack of data on the risk of bleeding in ACS patients treated with PCI in the clinical reality world of china
Thereforethe present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI
The present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI
This study will provide sufficient and reliable evidence for the risk of bleeding and the choice of antithrombotic drugs in ACS patients undergoing PCI in China and provide a reference for individual antithrombotic therapy after PCI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None